What is the typical timeframe for Veozah (generic name) to alleviate vasomotor symptoms in a female patient?

Timeframe for Veozah to Alleviate Vasomotor Symptoms

Veozah (fezolinetant) begins reducing vasomotor symptoms within 1 week of starting treatment, with statistically significant improvements in both frequency and severity observed at week 4 and maintained through week 12 and beyond. 1

Onset of Action and Treatment Timeline

• Week 1: Initial improvements in vasomotor symptom frequency and severity are detectable as early as 1 week after initiating fezolinetant treatment 1

• Week 4: Significant reductions are clearly established by week 4:

  • Fezolinetant 30 mg reduces vasomotor symptom frequency by approximately 1.87 episodes more than placebo 1
  • Fezolinetant 45 mg reduces frequency by approximately 2.07 episodes more than placebo 1
  • Both doses significantly reduce symptom severity compared to placebo (p<0.012 for 30 mg, p=0.002 for 45 mg) 1

• Week 12: Maximal benefit is evident by 12 weeks:

  • Fezolinetant 30 mg reduces frequency by 2.39 episodes more than placebo 1
  • Fezolinetant 45 mg reduces frequency by 2.55 episodes more than placebo 1
  • Severity reductions remain statistically significant for both doses 1

• Long-term maintenance: The therapeutic effect is sustained through 52 weeks of continuous treatment, demonstrating durability of response 1

Clinical Context and Comparison

The rapid onset within 1 week distinguishes fezolinetant from some other non-hormonal options. This is clinically meaningful because:

• Traditional non-hormonal treatments like SSRIs/SNRIs and gabapentin typically require several weeks to achieve therapeutic effect 2, 3
• Hormone therapy remains the most effective treatment overall (approximately 75% reduction in vasomotor symptoms), but fezolinetant provides a non-hormonal alternative with demonstrated efficacy of approximately 40-65% reduction 4
• The neurokinin 3 receptor antagonist mechanism allows for central thermoregulatory modulation without hormonal effects 5

Important Clinical Considerations

• Patients should be counseled to expect some improvement within the first week, but optimal benefit requires at least 4 weeks of continuous therapy 1
• Treatment should be continued for at least 12 weeks to fully assess therapeutic response before considering dose adjustment or alternative therapies 1
• The 45 mg dose shows numerically greater reductions in both frequency and severity compared to 30 mg, though both doses are effective 1, 6
• Adverse events are generally mild, with low incidence of liver enzyme elevations that are typically asymptomatic and transient 1